Drug intelligence / Profile preview

GV550

Development stage: Phase 1
Modality: Small Molecules
Administration: Ophthalmic (inferred From Indication; Not Explicitly Confirmed)

Overview

GV550 is an experimental drug currently under investigation for its potential therapeutic benefits. Publicly available information is limited, but it is being studied for the treatment of acute adenoviral keratoconjunctivitis, a viral infection of the eye that causes inflammation of the cornea and conjunctiva. The precise mechanism of action, chemical structure, and detailed pharmacological profile have not been disclosed in public sources[1][2].

Brand names: VirganZirgan
Other names: GV 550GV550GV-550

Targets

Herpesvirus DNA polymeraseHSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))DNA polymerase family

Beyond the preview

Go deeper on GV550.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GV550.